Document Detail


A pilot study for the effects of donepezil therapy on cerebral and optic nerve head blood flow, visual field defect in normal-tension glaucoma.
MedLine Citation:
PMID:  20415624     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate the effect of donepezil hydrochloride, an agent for the treatment of Alzheimer's disease (AD), on the cerebral and optic nerve head (ONH) blood flow, visual field defect in normal-tension glaucoma (NTG) patients with decreased cerebral blood flow (CBF) that demonstrates an AD-like perfusion pattern. METHODS: The subjects were 5 NTG patients who exhibited AD-like decreased CBF upon (123)I-iodoamphetamine single photon emission computed tomography ((123)I-IMP SPECT). Donepezil hydrochloride (5 mg/day) was prescribed for each patient during a period of 12 months. Intraocular pressure (IOP), mean deviation (MD) of the Humphrey visual field, ONH blood flow determined by a laser speckle flowgraphy, and regional CBF (rCBF) determined by (123)I-IMP SPECT were measured before and every 6 months during the treatment. RESULTS: MD, ONH blood flow, and rCBF were improved significantly after 6 months of the treatment, although IOP did not change significantly. No deterioration of NTG morbidity was found in any of the measured parameters after 12 months of the treatment. CONCLUSIONS: Oral administration of donepezil hydrochloride in NTG patients might prevent deterioration of visual field defect, ONH blood flow, and rCBF in the temporal, parietal, and posterior lobes. This pilot study suggested the possibility that donepezil hydrochloride might ameliorate glaucomatous optic neuropathy in NTG.
Authors:
Yukiko Yoshida; Tetsuya Sugiyama; Keita Utsunomiya; Yasuharu Ogura; Tsunehiko Ikeda
Related Documents :
10708924 - Reduced regional cerebral blood flow in non-psychotic violent offenders.
8965204 - Nonlinearity correction of brain perfusion spect based on permeability-surface area pro...
1856884 - Role of nucleus basalis in cholinergic control of cortical blood flow.
8513134 - In vivo visualization of acetylcholinesterase with positron emission tomography.
8977484 - Role of blood components in ocular silicone oil emulsification. studies on an in vitro ...
8769804 - Changes in regional hemodynamics after nitric oxide inhibition during ovine bacteremia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  26     ISSN:  1557-7732     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-26     Completed Date:  2010-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  187-92     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, Ujigawa Hospital, vji, Kyoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Blood Flow Velocity / drug effects
Brain / blood supply*
Cerebrovascular Circulation / drug effects
Cholinesterase Inhibitors / therapeutic use*
Female
Humans
Indans / therapeutic use*
Intraocular Pressure / drug effects
Iofetamine / diagnostic use
Laser-Doppler Flowmetry
Low Tension Glaucoma / drug therapy*,  physiopathology*
Male
Optic Disk / blood supply*
Pilot Projects
Piperidines / therapeutic use*
Radiopharmaceuticals / diagnostic use
Regional Blood Flow / drug effects
Tomography, Emission-Computed, Single-Photon
Vision Disorders / prevention & control*
Visual Fields / drug effects
Chemical
Reg. No./Substance:
0/Cholinesterase Inhibitors; 0/Indans; 0/Piperidines; 0/Radiopharmaceuticals; 120011-70-3/donepezil; 95896-48-3/Iofetamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Topical cyclosporine 0.05% for the prevention of dry eye disease progression.
Next Document:  Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative ag...